International scoring system for evaluating prognosis in myelodysplastic syndromes.

Despite multiple disparate prognostic risk analysis systems for evaluating clinical outcome for patients with myelodysplastic syndrome (MDS), imprecision persists with such analyses. To attempt to improve on these systems, an International MDS Risk Analysis Workshop combined cytogenetic, morphological, and clinical data from seven large previously reported risk-based studies that had generated prognostic systems. A global analysis was performed on these patients, and critical prognostic variables were re-evaluated to generate a consensus prognostic system, particularly using a more refined bone marrow (BM) cytogenetic classification. Univariate analysis indicated that the major variables having an impact on disease outcome for evolution to acute myeloid leukemia were cytogenetic abnormalities, percentage of BM myeloblasts, and number of cytopenias; for survival, in addition to the above, variables also included age and gender. Cytogenetic subgroups of outcome were as follows: "good" outcomes were normal, -Y alone, del(5q) alone, del(20q) alone; "poor" outcomes were complex (ie, > or = 3 abnormalities) or chromosome 7 anomalies; and "intermediate" outcomes were other abnormalities. Multivariate analysis combined these cytogenetic subgroups with percentage of BM blasts and number of cytopenias to generate a prognostic model. Weighting these variables by their statistical power separated patients into distinctive subgroups of risk for 25% of patients to undergo evolution to acute myeloid leukemia, with: low (31% of patients), 9.4 years; intermediate-1 (INT-1; 39%), 3.3 years; INT-2 (22%), 1.1 years; and high (8%), 0.2 year. These features also separated patients into similar distinctive risk groups for median survival: low, 5.7 years; INT-1, 3.5 years; INT-2, 1.2 years; and high, 0.4 year. Stratification for age further improved analysis of survival. Compared with prior risk-based classifications, this International Prognostic Scoring System provides an improved method for evaluating prognosis in MDS. This classification system should prove useful for more precise design and analysis of therapeutic trials in this disease.

[1]  M. Sanz,et al.  Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. , 1989, Blood.

[2]  D. Oscier.  Myelodysplastic syndromes. , 2007, Bailliere's clinical haematology.

[3]  M. Oken,et al.  Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia , 1988, British journal of haematology.

[4]  R. Larson,et al.  Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo. , 1988, Leukemia.

[5]  H. Gralnick,et al.  The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: Proposals by the French ‐ American ‐ British Cooperative Leukaemia Group , 1994, British journal of haematology.

[6]  A. Julià,et al.  Myelodysplastic syndromes: a study of 101 cases according to the FAB classification , 1985, British journal of haematology.

[7]  S. Asano,et al.  Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. , 1993, Leukemia.

[8]  D. Hossfeld,et al.  Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with de novo myelodysplastic syndrome. , 1990, Cancer genetics and cytogenetics.

[9]  J. Rowley,et al.  Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes , 1986 .

[10]  D. Machin,et al.  Myelodysplastic syndromes: a scoring system with prognostic significance , 1985, British journal of haematology.

[11]  D. Rosenthal,et al.  Chronic myelomonocytic leukemia. , 1990, Leukemia.

[12]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[13]  C. Declercq,et al.  Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very‐low‐risk group using standard mortality ratio techniques , 1996, British journal of haematology.

[14]  O. Garson,et al.  The prognostic significance of deletion of the long arm of chromosome 20 in myeloid disorders. , 1994, Leukemia.

[15]  B. Coiffier,et al.  Dysmyelopoietic syndromes a search for prognostic factors in 193 patients , 2006, Cancer.

[16]  G. Tricot,et al.  The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations , 1985, British journal of haematology.

[17]  J. Armitage,et al.  Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases , 1985, Cancer.

[18]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .

[19]  K. United.  Loss of the Y chromosome from normal and neoplastic bone marrows , 1992, Genes, chromosomes & cancer.

[20]  E. Wattel,et al.  De novo myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 20: a subtype of MDS with distinct hematological and prognostic features? , 1993, Leukemia research.

[21]  G. Tricot,et al.  The 5q-anomaly. , 1985, Cancer genetics and cytogenetics.

[22]  H. Berghe,et al.  A new hematologic syndrome with a distinct karyotype: the 5 q--chromosome. , 1975, Blood.

[23]  G. Tricot,et al.  Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis , 1985, British journal of haematology.

[24]  A. Duhamel,et al.  Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. , 1993, Leukemia.

[25]  J. Hermans,et al.  Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases , 1987, British journal of haematology.

[26]  M. Pfeilstöcker,et al.  Cross‐validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics , 1999, British journal of haematology.

[27]  M. Sanz,et al.  Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors , 1990, British journal of haematology.

[28]  R. Beuscart,et al.  Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Rowley,et al.  Clinical-cytogenetic correlations in myelodysplasia (preleukemia). , 1989, Cancer genetics and cytogenetics.

[30]  D. Oscier.  5 Myelodysplastic syndromes , 1987 .

[31]  U. Germing,et al.  Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. , 1992, Leukemia.